| Field | Specification |
|---|---|
| Target | |
| Alternative names | SCE-963; Cefotiam Dihydrochloride |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C18H23N9O4S3 |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Cefotiam, also known as SCE-963 or Cefotiam Dihydrochloride, is a parenteral cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria[1][2]. It has the molecular formula C18H23N9O4S3 and a molecular weight of 525.63 g/mol.
Physical & Chemical Properties
| CAS Number | 61622-34-2 |
|---|---|
| Molecular Formula | C18H23N9O4S3 |
| Molecular Weight | 525.63 g/mol |
| SMILES | O=C(C(N12)=C(CSC3=NN=NN3CCN(C)C)CS[C@]2([H])[C@H](NC(CC4=CSC(N)=N4)=O)C1=O)O |
| Target | β-lactam |
| Signaling Pathway | Anti-infection |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
Cefotiam (SCE-963; 0-6.25μg/mL; 8 h) shows antibacterial activity against P. mirabilis IFO 3849, with a MIC of 1.56 μg/mL[1]. Cefotiam (0-6.25μg/mL; 8 h) is highly active against both Staph. aureus (27 strains) and Staph. albus (8 strains), with MIC values of 0.5-1 μg/mL and MICs of 0.25-0.5 μg/mL, respectively. MIC values fall in the range 0.06-4 μg/mL for all 29 strains of haemolytic streptococci, as well as 9 strains of pneumococci and 6 strains of Streptococcus viridans[2].
In Vivo
Cefotiam can cure urinary tract infection with P. mirabilis in mice (SCE-963; 12.5-800 mg/kg; i.h.; twice a day for 5 d), reducing or completely eradicating bacteria in the bladder walls and kidneys[1].
| Animal Model | Female CF1/b mice with P. mirabilis xenograft[1] |
|---|---|
| Dosage | 12.5, 25, 50, 100, 200, 400 and 800 mg/kg |
| Administration | Subcutaneous injection; twice a day, for 5 days |
| Result | Reduced or complete eradicated bacteria in the bladder walls and kidneys of mice sacrificed the day after treatment was terminated. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
